💹 NASDAQ: BRTX - Breaking News!

[View online]( [UNSUBSCRIBE]( ALERT: NASDAQ: BRTX BRTX is Addressing TWO Common Ailments that Plague Millions of Americans with MAJOR Near-Term Data Catalysts  Greetings All,  The once-in-a-century pandemic thrust the healthcare industry into the teeth of the storm. It is an industry that is called recession-proof because who doesn’t need healthcare?  In fact, the impact of inflation on the broader economy has significantly driven up input costs in healthcare. According to [McKinsey & Company]( analysis estimates, the annual US national health expenditure is likely to be $370 billion higher by 2027 due to the impact of inflation compared with pre-pandemic projections.  One special area in healthcare that is getting more and more attention isregenerative medicine, a market that was worth [$16.9 billion]( in 2021.  Regenerative medicine [harnesses]( the body’s amazing ability to heal itself, using cutting-edge technology to apply this regenerative power to prompt the body to recover from diseases previously uncured.  This brings attention to an under-the-radar company that is innovating in the cutting-edge regenerative medicine field.  Trading at a few dollars, and with [a small trading float]( this little-known NASDAQ company called BioRestorative Therapies Inc. (NASDAQ: BRTX) is working on products that may be solutions to conditions that affect millions of Americans with lower back pain and diabetes.  Lower back pain and obesity are major health crises. Lower back pain is the [leading]( cause of disability worldwide, and obesity has been identified as a [national security threat]( by the Department of Defense.  Many big companies have realized the market potential for finding ways to improve the lives of those suffering from these conditions.  BioRestorative Therapies Inc. (NASDAQ: BRTX)’s novel drug BRTX-100,which is approved by the Food and Drug Administration (FDA) to enter Phase 2 clinical trials, targets damaged and degenerating discs.  The Company is well into its trial, a 99-patient prospective, randomized, double-blinded, controlled study, the gold standard of its kind!  BRTX’s other product — ThermoStem — has highly promising results in the treatment of obesity and related diseases. Obesity affects over [40% of Americans]( and the company is [developing]( a novel stem-cell population — brown adipose tissue — that shows signs of regulating metabolic activity and reducing excess fat.  Companies such as Pfizer Inc. (NYSE: PFE), Novo Nordisk (NYSE: NVO) and Vertex Inc. (NASDAQ: VRTX) seem to have recognized the market potential for potential obesity treatments and are actively looking for the next breakthrough in obesity therapies. BRTX may have it.  With top-tier growth potential in its future, BioRestorative Therapies Inc. (NASDAQ: BRTX) may be the most exciting company to have your eyes on in the stem-cell space!     BREAKING NEWS! BioRestorative Therapies Enters Agreement with Regenexx, Granting BRTX Exclusive License Rights for Intellectual Property Related to the Development and Commercialization of its BRTX-100® Disc Program to Treat Chronic Lumbar Disc Disease  BioRestorative Therapies, Inc -- Intellectual Property Provides a Cell-Based Therapeutic Platform Designed to Target All Avascular Zones-- MELVILLE, N.Y., Dec. 05, 2022 (GLOBE NEWSWIRE) -- [BioRestorative Therapies, Inc.]( (“BioRestorative” or the “Company”) (NASDAQ: [BRTX]( a clinical stage company focused on stem cell-based therapies, today announced an agreement with [Regenexx, LLC]( pursuant to which the license rights granted by Regenexx to the Company for intellectual property developed to address chronic lumbar disc disease have been made exclusive. The intellectual property now exclusively licensed to the Company represents important technological framework for BRTX’s disc/spine technology related to the Company’s BRTX-100® lead clinical program, currently in a Phase 2 trial with approximately 15 sites selected across the United States. The intellectual property was developed in the lab of [Dr. Christopher Centeno](. Dr. Centeno has been a leader in the field of cellular therapy for musculoskeletal indications for over 17 years. “This is an important event for BioRestorative. We are thrilled to now have through this agreement an exclusive license with regard to Regenexx’s technology,” said [Lance Alstodt]( Chief Executive Officer at BioRestorative. “With this agreement, coupled with our unique in-house research and manufacturing capabilities, we aim to create a new generation of cell-based products to induce long-term and sustained pain relief for patients suffering from musculoskeletal indications. Approximately $40 billion is spent annually on invasive surgical procedures. With BRTX-100, the Company is seeking to provide a paradigm shifting, non-invasive solution to millions of patients worldwide.”  The BRTX-100 platform is a cell-based technology that utilizes low oxygen (hypoxia) to engineer the cells’ modulation strategy to repress or activate transcription of target genes related to tissue remodeling. Data from early investigator-initiated human studies suggest a potential for this platform to regulate target hypoxia-dependent gene expression as a means to improve upon both the efficacy and safety of first-generation cell-based therapies. “Regenexx is excited to have granted exclusive license rights to BioRestorative and support their efforts as they continue to develop the technology through the regulatory pathway. We have a great deal of clinical experience with positive clinical outcomes using this technology. We are grateful that BioRestorative is working to provide access to this product to the many patients who are currently left with minimal options that are less effective and more economically inefficient.” said Christopher Centeno MD, Founder and Chief Medical Officer for Regenexx, LLC. Full Press here: [( [READ FULL PROFILE ON NASDAQ: BRTX](     Copyright 2022 © TopStockTips.com is owned and operated by the owner of CareBear Marketing Group LLC. Disclaimer and Privacy For more Information please contact Support@TopStockTips.com This website provides information about the stock market and other investments. This website does not provide investment advice and should not be used as a replacement for investment advice from a qualified professional. This website is for informational purposes only. The Author of this website is not a registered investment advisor and does not offer investment advice. You, the reader, bear responsibility for your own investment decisions and should seek the advice of a qualified securities professional before making any investment. Nothing on this website should be considered personalized financial advice. Any investments recommended here in should be made only after consulting with your personal investment advisor and only after performing your own research and due diligence, including reviewing the prospectus or financial statements of the issuer of any security.  CareBear Marketing Group, its managers, its employees, affiliates, and assigns (collectively "The Company") do not make any guarantee or warranty about the advice provided on this website or what is otherwise advertised above. To the maximum extent permitted by law, the Company disclaims all liability in the event any information, commentary, analysis, opinions, advice and/or recommendations provided herein prove to be inaccurate, incomplete, or unreliable, or result in any investment or other losses. You received this message as part of your subscription to TST. TST is a free financial news and information website. We do not directly sell any products or offer any personal financial advice, nor do we advocate the purchase or sale of any security or investment for any specific individual. We also do not make any guarantee or warranty about what is advertised above. If you have questions or concerns about a product you’ve seen in one of our emails, we encourage you to reach out to that company directly.  Disclaimer – Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated, and edited by CareBear Marketing Group. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” or “TST” refers to CareBear Marketing Group. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature and are therefore unqualified to give investment recommendations. Companies with low prices per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service, you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website. We do not advise any reader to take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and its owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares, we will list the information relevant to the stock and the number of shares here. We do not own any shares in BRTX. We have been currently compensated up to Two-Hundred Fifty-Thousand Dollars Cash ($250,000) via bank wire transfer from a third-party Open Market Media Group for a 3 Day Marketing Program regarding BRTX with a start date of 12/02/2022 to 12/06/2022. TST’s business model is to receive financial compensation to promote public companies. This compensation is a major conflict of interest in our ability to be unbiased regarding our alerts. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, TST often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice. , Rua Frei Tome de Jesus N18 1Dto, 1700-215, Lisboa, Portugal You may [unsubscribe]( or [change your contact details]( at any time. Powered by:[GetResponse](